Phaseline

Companies › Ionis Pharmaceuticals

Ionis Pharmaceuticals: clinical trials, targets and expected readouts

12 active drug programs in 18 registered trials: 11 Phase 3, 6 Phase 1, 1 Phase 2; Neurology, Metabolic and endocrine, Psychiatry, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Donidalorsen–Phase 3Hereditary Angioedema; Hereditary Angioedema (HAE)Dec 2026
Olezarsen
Apolipoprotein C-III mRNA antisense inhibitor
APOC3Phase 3Severe Hypertriglyceridemia; Familial Chylomicronemia SyndromeMar 2027
obudanersen (ION582)
antisense oligonucleotide targeting paternal UBE3A mRNA to restore maternal UBE3A expressi
UBE3APhase 3Angelman SyndromeAug 2027
ION363
Antisense oligonucleotide targeting FUS mRNA
FUSPhase 3Amyotrophic Lateral SclerosisMar 2028
Eplontersen
Transthyretin mRNA antisense inhibitor
TTRPhase 3Hereditary Transthyretin-Mediated Amyloid PolyneuropathyAug 2029
zilganersen (ION373)
Antisense oligonucleotide targeting GFAP mRNA
GFAPPhase 3Alexander DiseaseJul 2034
ION775
APOC3 antisense oligonucleotide
–Phase 2HypertriglyceridemiaSep 2027
ION717–Phase 1Prion DiseaseApr 2027
ION440
Antisense oligonucleotide targeting MECP2
MECP2Phase 1Methyl CpG Binding Protein 2 (MECP2) Duplication SyndromeSep 2027
ION464
unclear - antisense oligonucleotide (likely, given Ionis Pharmaceuticals' focus)
–Phase 1Multiple System AtrophySep 2027
ION356
Antisense oligonucleotide targeting PLP1
–Phase 1Pelizaeus-Merzbacher DiseaseJun 2028
ION337
SCN1A antisense oligonucleotide
–Phase 1Dravet SyndromeDec 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05392114DonidalorsenPhase 3Hereditary AngioedemaImmunologyDec 2026
NCT05681351OlezarsenPhase 3Severe HypertriglyceridemiaMetabolic and endocrineMar 2027
NCT06153966ION717Phase 1Prion DiseaseInfectious diseaseApr 2027
NCT05185843OlezarsenPhase 3Familial Chylomicronemia SyndromeMetabolic and endocrineJun 2027
NCT06914609obudanersen (ION582)Phase 3Angelman SyndromeOtherAug 2027
NCT06430385ION440Phase 1Methyl CpG Binding Protein 2 (MECP2) Duplication SyndromePsychiatrySep 2027
NCT07604974ION775Phase 2HypertriglyceridemiaMetabolic and endocrineSep 2027
NCT04165486ION464Phase 1Multiple System AtrophyNeurologySep 2027
NCT05130450OlezarsenPhase 3Familial Chylomicronemia SyndromeMetabolic and endocrineFeb 2028
NCT04768972ION363Phase 3Amyotrophic Lateral SclerosisNeurologyMar 2028
NCT07782827obudanersen (ION582)Phase 3Angelman SyndromeOtherMay 2028
NCT06150716ION356Phase 1Pelizaeus-Merzbacher DiseaseMetabolic and endocrineJun 2028
NCT05127226obudanersen (ION582)Phase 1Angelman SyndromeOtherMar 2029
NCT07298447DonidalorsenPhase 3Hereditary Angioedema (HAE)ImmunologyJun 2029
NCT05071300EplontersenPhase 3Hereditary Transthyretin-Mediated Amyloid PolyneuropathyNeurologyAug 2029
NCT07727538OlezarsenPhase 3Familial Chylomicronemia SyndromeMetabolic and endocrineAug 2030
NCT07531745ION337Phase 1Dravet SyndromeNeurologyDec 2030
NCT04849741zilganersen (ION373)Phase 3Alexander DiseaseNeurologyJul 2034

From the company's SEC filings

Cash and short-term investments of $1.9bn on 2026-09-30; operating cash outflow about $546m a year; runway about 41 months at that burn, to Mar 2030; 6 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

MECP2 (1) APOC3 (1) UBE3A (1) GFAP (1) FUS (1) TTR (1)

Companies with the same targets

Alnylam Pharmaceuticals AstraZeneca Taysha Gene Therapies Neurogene Eli Lilly Arrowhead Pharmaceuticals Fujian Shengdi Pharmaceutical MavriX Bio OHB Pediatrics Ultragenyx Pharmaceutical

Companies built like this

Arrowhead Pharmaceuticals Biogen Praxis Precision Medicines Alnylam Pharmaceuticals Amylyx Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.